Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns
Paradigm4 has launched its REVEAL™: Multi-Omics app, allowing researchers to undertake advanced, cross-study analyses and enable quick searches for genes and proteins across all integrated public reference and proprietary datasets.
BOSTON — Paradigm4 has today unveiled REVEAL™: Proteomics, the newest use case specific app powered by the Paradigm4 FLASH™ high-performance bioinformatics platform. REVEAL: Proteomics unlocks the power of advanced mass spec proteomics by simplifying cross sample and cross study searching for protein isoforms as potential biomarkers for drug response or
Paradigm4 announces the general availability of flexFS, a hyperscale file system designed for AI/ML and large file data workloads, providing unparalleled throughput at 50% lower cost
